Jae Kim is a Partner in the Philadelphia and Washington D.C. offices of DLA Piper. Her food and drug practice is primarily focused on regulatory compliance matters impacting clients that develop, manufacture, and distribute FDA-regulated products such as medical devices, drugs, food and beverage, cosmetics, and dietary supplements. She also has deep experience in navigating complex regulatory requirements that apply to products and goods that are regulated by USDA, TTB, and DEA.Jae’s knowledge and experience across various industries and sectors are invaluable for clients who are seeking to launch products that intersect with two or more product categories, especially if they need strategic advice on how to best position novel products to achieve their business goals. She counsels companies in regulated industries on issues that arise throughout the product life cycle, from product development to postmarket compliance. She has particular expertise with state and federal licensing and registration, advertising and promotion, agreements pertaining to quality, safety, and regulatory issues, pharmacovigilance, recall management, and government enforcement actions.In addition to her regulatory practice, Jae has extensive transactional experience as a subject matter specialist, conducting FDA due diligence on behalf of companies seeking to acquire or invest in companies with a portfolio of regulated products. She also has experience in providing regulatory advice and counseling for companies facing internal investigations, litigation, and arbitrations.Jae is the Co-Vice Chair of AAPEX, the Firm's Asian American Pacific Islander Resource Group. Outside the office, she is actively involved in the regulatory community and holds committee positions with the Food and Drug Law Institute (FDLI) and the Philadelphia Metro Chapter of Women in Bio.